ClinicalTrials.gg
DrugBiological

Granulocyte-Macrophage Colony-Stimulating Factor clinical trials

studies test it
120
open now
10
in phase 3
5
first study started
1998

Counted the way a researcher would: Granulocyte-Macrophage Colony-Stimulating Factor with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.

This browser remembers your choice.

How each study uses Granulocyte-Macrophage Colony-Stimulating Factor is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Granulocyte-Macrophage Colony-Stimulating Factor studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

GM-CSF
67
Sargramostim
23
Leukine
20
GM-CSF (sargramostim)
6
granulocyte-macrophage colony stimulating factor
5

In one entry with another drug

Given together, or one or the other

Naxitamab and GM-CSF in combination with irinotecan and temozolomide
2

Studies by the year they started

117 studies that test it; most in 2004 (12)

Studies that test Granulocyte-Macrophage Colony-Stimulating Factor, by start year
YearStudies
19981
19993
20012
20025
20034
200412
20053
20068
20078
20081
20092
20101
20117
20128
20136
20145
20153
20163
20178
20184
20193
20217
20227
20231
20242
20251
20262

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
31
Phase 2
85
Phase 3
5
Phase 4
5
No phase
7

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 17 · Other 103

M.D. Anderson Cancer Center (8) · Emory University (5) · Memorial Sloan Kettering Cancer Center (4) · Second Affiliated Hospital of Soochow University (4) · Sellas Life Sciences Group (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · University of Virginia (3) · University Hospital Tuebingen (3)

Often tested with

Tested in the same studies.

Interleukin-2 (10) · Naxitamab (7) · Temozolomide (6) · Cyclophosphamide (5) · Rituximab (5) · Ipilimumab (4) · Granulocyte Colony-Stimulating Factor (4) · Irinotecan (4)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4

Studies that test Granulocyte-Macrophage Colony-Stimulating Factor.

Studies

Open first, then newest update. How each study uses Granulocyte-Macrophage Colony-Stimulating Factor is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 120

See all 120 studies that test Granulocyte-Macrophage Colony-Stimulating Factor →

Given beside what is tested · 56 — Granulocyte-Macrophage Colony-Stimulating Factor is usual care or a partner of the new treatment

Showing 20 of 56.

As the comparator · 4 — what is tested is compared with Granulocyte-Macrophage Colony-Stimulating Factor

What changed recently

From the registry's own updates since Oct 20, 2026.